Company intelligence / Profile preview

Sagimet Biosciences

San Mateo, California, United Statessagimet.com ↗

Ownership: Public · SGMT
Employees: ~50
Development stage: Phase 3

Overview

Sagimet Biosciences has demonstrated positive results in Phase 2 trials for its lead candidate denifanstat in MASH, with the FASCINATE‑1 and FASCINATE‑2 studies showing good tolerability and efficacy. Denifanstat received FDA Breakthrough Therapy Designation for MASH based on these results. The company has initiated or plans to initiate multiple Phase 3 trials for denifanstat in both MASH and acne. Additional programs are advancing toward IND-enabling or early clinical stages[1][10].

Therapeutic areas: OncologyDermatologyMetabolic Disorders
Modalities: Small molecules (Fatty Acid Synthase [FASN] inhibitors)
Industry: Biotech

Drug pipeline

6 assets

denifanstat

5 more assets in the full pipeline.

Request access →

Partnerships

Ascletis Pharma Inc.: Licensed development/commercialization rights to all indications in Greater China; conducting clinical trials of denifanstat for GBM and acne[6][9].Collaborations with academic institutions mentioned but not specified by name[5].

Financials

Market cap: $353.8M
Total revenue: $0
Enterprise value: $115.7M

Beyond the preview

Go deeper on Sagimet Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sagimet Biosciences.

Explore the full profile